UNSPSC 51151663: Tifenamil

This classification denotes an antimuscarinic agent with the molecular formula C20H25NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GX4D5197DT, chemically known as benzeneethanethioic acid, alpha-phenyl-, s-(2-(diethylamino)ethyl) ester but generally known as thiphenamil, which bears US NIH Compound Identifier 11061. European Medicines Agency schedules Tifenamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11038MIG.

The term TIFENAMIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Most nations schedule tifenamil under HS 29309085 and SITC 51549. SMILES: CCN(CC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.

UNSPSC 51151663 Tifenamil, a Commodity code, represents pharmaceutical products and related health-system procurement that state and local governments buy to support community health and pharmacy benefit initiatives. Recent solicitations under this code show activity in naloxone procurement and pharmaceutical distribution systems. The issuing bodies include county health departments and state health and human services commissions pursuing both direct product acquisition and program-level pharmacy contracting arrangements.

Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with vendors required to submit electronic bids including all shipping and delivery costs. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, requesting information from potential vendors about their capacity to enter direct contracts with self-insured health plans and state agencies outside existing pharmacy benefit manager and group purchasing organization arrangements. Activity under this code centers in Florida and Texas, with procurement spanning county health departments and state health agencies. The mix reflects both direct-purchase solicitations for specific pharmaceutical products and exploratory market-intelligence gathering for larger pharmacy benefit program structures.